Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Amber Tong
amber@endpointsnews.com
@AmberTongPW
Amber Tong on LinkedIn
author articles
Gilead quashes microcap biotech's hope of partnering on oral Covid-19 drug
3 years ago
Deals
After pivoting from Alzheimer's to bone conditions, biotech pivots again — and halves its headcount
3 years ago
People
Deals
Pfizer-backed decentralized cooperative raises $4.1M to fund longevity research
3 years ago
Financing
Eric Lander to return to Broad Institute, one year after White House exit over bullying allegations
3 years ago
People
Late Friday approval; Trio of biotechs wind down; Stem cell pioneer finds new frontier; Biotech icon to retire; and ...
3 years ago
Weekly
F-star gets down to the wire with $161M sale to Chinese buyer as national security concerns linger
3 years ago
Deals
Oral drug for diabetic retinopathy flunks PhII, but biotech wants to go into PhIII with new endpoint
3 years ago
R&D
Patient death spurs trial halt for Magenta Therapeutics
3 years ago
R&D
J&J quietly punts a pair of early-stage bispecifics for solid tumors
3 years ago
R&D
Pharma
KSQ Therapeutics sells early-stage targeted therapies to Japan's Ono
3 years ago
Deals
Crushed by PhIII antibiotic flop, PolyPid says it got FDA support for a comeback — by focusing on subgroup
3 years ago
R&D
Failed deal, bidding war paved the way for Ipsen's $952M rare disease buyout
3 years ago
Deals
Updated: J&J axes four-year discovery alliance with Morphic
3 years ago
Deals
Updated: Takeda bets $400M cash on colorectal cancer drug in boost to China's Hutchmed
3 years ago
Deals
China
An Alzheimer’s rejection; Our #JPM23 dispatches; Count Moderna in for RSV; Biotech layoffs persist; and more
3 years ago
Weekly
As monotherapy data disappoint, Cyteir lets go of 35 staffers, goes all in on ovarian cancer
3 years ago
People
Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift'
3 years ago
People
Horizon claims mid-stage victory in rare disease, lines up PhIII for new owners at Amgen
3 years ago
R&D
Ipsen has go/no-go decision to make after biotech partner's Parkinson's drug flunks PhIIb
3 years ago
R&D
The conference is back. What about the industry? Taking the biotech pulse at #JPM23
3 years ago
Financing
In Focus
Bankrupt PhaseBio settles with investor-partner, handing off late-stage drug
3 years ago
Deals
Law
Ready to expand, GenScript raises $224M for CDMO focused on antibodies, cell and gene therapies
3 years ago
Financing
China
Cancer vaccine developer jumps to Nasdaq via reverse merger
3 years ago
Deals
Latest news on Covid boosters safety signal; AstraZeneca leads trio of M&A; The biggest news out of #JPM23; and more
3 years ago
Weekly
First page
Previous page
17
18
19
20
21
22
23
Next page
Last page
